Clinical Assessment of Mocravimod As a Victim of Drug-Drug Interactions Via CYP3A Metabolism and Transporters

被引：0
|
作者：
Huntjens, Dymphy [1 ]
Oehen, Stephan [2 ]
Kueenburg, Elisabeth [3 ]
机构：
[1] Priothera SAS, Valkenburg, Netherlands
[2] Priothera SAS, Basel, Switzerland
[3] Priothera SAS, St Louis, France
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-193899
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5774 / 5775
页数：2
相关论文
共 50 条
  • [21] Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model
    Yamazaki, Shinji
    Johnson, Theodore R.
    Smith, Bill J.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (10) : 1417 - 1429
  • [22] Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition
    Josephson, F.
    JOURNAL OF INTERNAL MEDICINE, 2010, 268 (06) : 530 - 539
  • [23] Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib
    Morcos, Peter N.
    Cleary, Yumi
    Guerini, Elena
    Dall, Georgina
    Bogman, Katrijn
    De Petris, Luigi
    Viteri, Santiago
    Bordogna, Walter
    Yu, Li
    Martin-Facklam, Meret
    Phipps, Alex
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (03): : 280 - 291
  • [24] Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism
    Ya-nan Liu
    Jie Chen
    Jing Wang
    Qingqing Li
    Guo-xin Hu
    Jian-ping Cai
    Guanyang Lin
    Ren-ai Xu
    Archives of Toxicology, 2023, 97 : 2133 - 2142
  • [25] Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism
    Liu, Ya-nan
    Chen, Jie
    Wang, Jing
    Li, Qingqing
    Hu, Guo-xin
    Cai, Jian-ping
    Lin, Guanyang
    Xu, Ren-ai
    ARCHIVES OF TOXICOLOGY, 2023, 97 (08) : 2133 - 2142
  • [26] Steroid-tacrolimus drug-drug interaction and the effect of CYP3A genotypes
    Saqr, Abdelrahman
    Al-Kofahi, Mahmoud
    Mohamed, Moataz
    Dorr, Casey
    Remmel, Rory P.
    Onyeaghala, Guillaume
    Oetting, William S.
    Guan, Weihua
    Mannon, Roslyn B.
    Matas, Arthur J.
    Israni, Ajay
    Jacobson, Pamala A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (11) : 2837 - 2848
  • [27] Drug-Drug Interaction between VX-770 and CYP3A Modulators
    Chen, Yingxue
    Luo, Xia
    Dubey, Neeraj
    Zha, Jiuhong
    Yen, Karl
    Zhang, Jianbo
    Ordonez, Claudia
    Kumor, Karen M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1348 - 1348
  • [28] Renal drug transporters and their significance in drug-drug interactions
    Yin, Jia
    Wang, Joanne
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (05) : 363 - 373
  • [29] Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
    Mulford, Darcy J.
    Ramsden, Diane
    Zhang, Liming
    Michon, Ingrid
    Leifke, Eckhard
    Smith, Neila
    Jones, Hannah M.
    Scarpignato, Carmelo
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (04): : 532 - 544
  • [30] Quantitative Prediction of Drug-Drug Interactions Caused by CYP3A Induction Using Endogenous Biomarker 4β-Hydroxycholesterol
    Takubo, Hiroaki
    Taniguchi, Toshio
    Nomura, Yukihiro
    DRUG METABOLISM AND DISPOSITION, 2024, 52 (12) : 1438 - 1444
12345